Ratings Metagenomi, Inc.

Equities

MGX

US59102M1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
7.1 ^USD	+6.13%		+8.56%	0.00%

May. 07	HC Wainwright Starts Metagenomi With Buy Rating, $10 Price Target	MT
May. 03	North American Morning Briefing : Apple, Amgen -2-	DJ

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
METAGENOMI, INC.	0.00%	251M	-	-
MODERNA, INC.	+44.48%	54.04B		B-
LONZA GROUP AG	+43.57%	41.96B		A
IQVIA HOLDINGS INC.	-0.86%	41.92B		B
CELLTRION, INC.	-7.59%	28.35B		C
ICON PUBLIC LIMITED COMPANY	+12.30%	26.35B		B-
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	19B		B
BIO-TECHNE CORPORATION	+7.15%	13B		B+
MEDPACE HOLDINGS, INC.	+29.40%	12.28B		C+
UNITED THERAPEUTICS CORPORATION	+25.15%	12.19B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes